Zhou Le-Yuan, Zeng Zhao-Chong, Fan Jia, Chen Bing, Rao Sheng-xiang, He Jian, Yang Ping, Hou Jia-zhou, Wu Zhi-feng, Zhang Jian-ying, Hu Yong
Department of Radiation Oncology, Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai 200032, China.
BMC Cancer. 2014 Nov 25;14:878. doi: 10.1186/1471-2407-14-878.
The optimal treatment for adrenal metastases from hepatocellular carcinoma (HCC) has not been established. This study analyzed the effects of radiation therapy (RT) for such metastases and identified clinical features and predictors of survival in these patients.
We retrospectively investigated 55 patients with adrenal metastasis from HCC who had been treated with RT. Radiation doses to the adrenal lesions ranged from 26 to 60 Gy, while the intrahepatic lesions were treated by surgical resection, transarterial chemoembolization (TACE), liver transplantation, and/or RT. RT was conducted to adrenal lesions after their intrahepatic lesions were controlled more than 2 months. The parameters studied included survival rates and tumor responses to RT. The Kaplan-Meier method was used to evaluate survival rate and the Cox regression model was used to identify potential predictors of outcome.
The patients treated by RT had adrenal metastasis on the right side (41), the left (6), or on both sides (8). In all 55 patients, the median survival duration was 13.6 months and there was 100% pain relief after completion of RT. Adverse effects were mild to moderate. Unfavorable pretreatment predictors determined by univariate analysis were associated with multiple intrahepatic foci, metastases to additional organs, high γ-glutamyltransferase and alpha-fetoprotein levels, liver function of Child-Pugh classification B and uncontrolled primary HCC. By multivariate analysis, unfavorable predictors were multiple intrahepatic foci, metastases to additional organs and uncontrolled primary HCC.
Radiotherapy as treatment for adrenal metastases in HCC is a good palliative therapy that is associated with reasonable safety. It appears reasonable that such patients should be considered to be treated with radiotherapy. Multiple intrahepatic foci, metastases to additional organs and uncontrolled primary HCC were unfavorable predictors.
肝细胞癌(HCC)肾上腺转移的最佳治疗方法尚未确定。本研究分析了放射治疗(RT)对此类转移灶的疗效,并确定了这些患者的临床特征和生存预测因素。
我们回顾性研究了55例接受RT治疗的HCC肾上腺转移患者。肾上腺病灶的放射剂量为26至60 Gy,而肝内病灶则通过手术切除、经动脉化疗栓塞(TACE)、肝移植和/或RT进行治疗。在肝内病灶得到控制超过2个月后,对肾上腺病灶进行RT。研究的参数包括生存率和肿瘤对RT的反应。采用Kaplan-Meier法评估生存率,采用Cox回归模型确定预后的潜在预测因素。
接受RT治疗的患者肾上腺转移位于右侧(41例)、左侧(6例)或双侧(8例)。在所有55例患者中,中位生存时间为13.6个月,RT完成后疼痛缓解率为100%。不良反应为轻至中度。单因素分析确定的不良预处理预测因素与多个肝内病灶、其他器官转移、高γ-谷氨酰转移酶和甲胎蛋白水平、Child-Pugh B级肝功能以及未控制的原发性HCC有关。多因素分析显示,不良预测因素为多个肝内病灶、其他器官转移和未控制的原发性HCC。
放射治疗作为HCC肾上腺转移的治疗方法是一种良好的姑息治疗方法,安全性合理。对这类患者考虑进行放射治疗似乎是合理的。多个肝内病灶、其他器官转移和未控制的原发性HCC是不良预测因素。